The Current Ratio as of November 2024 (TTM) for NewAmsterdam Pharma Company N.V. (NAMS) is 9.83

According to NewAmsterdam Pharma Company N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 9.83. This represents a change of 57.61% compared to the average of 6.24 of the last 4 quarters.

NewAmsterdam Pharma Company N.V. (NAMS) Historical Current Ratio (quarterly & annually)

How has NAMS Current Ratio performed in the past?

The mean historical Current Ratio of NewAmsterdam Pharma Company N.V. over the last ten years is 6.57. The current 9.83 Current Ratio has changed 14.87% with respect to the historical average. Over the past ten years (40 quarters), NAMS's Current Ratio was at its highest in in the December 2022 quarter at 12.64. The Current Ratio was at its lowest in in the April 2023 quarter at 0.

NewAmsterdam Pharma Company N.V. (NAMS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of NewAmsterdam Pharma Company N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NewAmsterdam Pharma Company N.V. (NAMS) Average Current Ratio

How has NAMS Current Ratio performed in the past?

The current Current Ratio of NewAmsterdam Pharma Company N.V. (NAMS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

NewAmsterdam Pharma Company N.V. (NAMS) Current Ratio vs. Peers

How is NAMS’s Current Ratio compared to its peers?

NewAmsterdam Pharma Company N.V.’s Current Ratio is less than Monte Rosa Therapeutics, Inc. (0), greater than Inventiva S.A. (6.56), greater than Cullinan Oncology, Inc. (0.95), less than Compass Therapeutics, Inc. (28.87), less than Replimune Group, Inc. (40.74), less than Crinetics Pharmaceuticals, Inc. (13.46), less than PureTech Health plc (16.09), greater than Merus N.V. (3.68), greater than Mineralys Therapeutics, Inc. (8.32), less than Eliem Therapeutics, Inc. (11.20), less than Anebulo Pharmaceuticals, Inc. (60.41), less than Janux Therapeutics, Inc. (13.46), less than Rezolute, Inc. (57.34), less than Molecular Partners AG (13.39), less than PepGen Inc. (14.58), greater than Cyteir Therapeutics, Inc. (7.45), less than null (21.89),

Build a custom stock screener for NewAmsterdam Pharma Company N.V. (NAMS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NewAmsterdam Pharma Company N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NewAmsterdam Pharma Company N.V. (NAMS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NewAmsterdam Pharma Company N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.